Beximco Pharmaceuticals Ltd Completion of the Acquisition of Nuvista Pharma (5723J)
April 03 2018 - 2:01AM
UK Regulatory
TIDMBXP
RNS Number : 5723J
Beximco Pharmaceuticals Ltd
03 April 2018
3 April 2018
BEXIMCO PHARMACEUTICALS LTD.
Completion of the acquisition of Nuvista Pharma Limited
Beximco Pharmaceuticals Limited ("BPL", "Beximco Pharma" or
"Company"; AIM Symbol: BXP LEI No. 213800IMBBD6TIOQGB56), the
fast-growing manufacturer of generic pharmaceutical products and
active pharmaceutical ingredients, today announces that, further to
the announcements made on 6 October 2017 and 19 January 2018, the
Company has completed the acquisition of a majority stake in
Nuvista Pharma Limited (Nuvista). A total of 10,013,474 Ordinary
Shares have been acquired from seven individual shareholders having
an aggregate holding of 85.22% of the Paid up Capital of
Nuvista.
Immediately after the acquisition, the Board of Nuvista was
reconstituted. The new five member board consists of four nominees
from Beximco Pharma and one nominee representing the government
shareholding in Nuvista.
For further information please visit www.beximcopharma.com or
enquire to:
Beximco Pharma
Nazmul Hassan MP, Managing Director
Tel: +880 2 58611001, ext.20080
SPARK Advisory Partners Limited (Nominated Adviser)
Mark Brady / Andrew Emmott
Tel: +44 (0)20 3368 3551 / 3555
Northland Capital Partners Limited (Broker)
Tom Price
Tel: +44 (0)20 3861 6625
FTI Consulting
Simon Conway / Victoria Foster Mitchell
Tel: +44 (0)20 3727 1000
Notes to Editors:
About Beximco Pharmaceuticals Limited
Founded in 1976 and based in Dhaka, Bangladesh, Beximco Pharma
manufactures and sells generic pharmaceutical formulation products
and active pharmaceutical ingredients. The Company also undertakes
contract manufacturing for multinational and leading global generic
pharmaceutical companies. The Company operates from a 23 acre site
in Dhaka and has manufacturing facilities for producing various
drugs in different delivery systems such as tablets, capsules,
liquids, semi-solids, intravenous fluids, metered dose inhalers,
dry powder inhalers, sterile ophthalmic drops, prefilled syringes,
injectables, nebuliser solutions, oral soluble films etc. Ensuring
access to quality medicines is the powerful aspiration that
motivates 3,800 employees of the Company.
Beximco Pharma's state-of-the-art manufacturing facilities are
certified by global regulatory authorities of USA, Europe,
Australia, Canada, GCC and Latin America, among others. The
Company's products are sold to retail outlets, medical institutions
and other pharmaceutical manufacturers in Bangladesh, in regional
markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and
Myanmar and in other markets overseas, principally in South East
Asia, including Singapore, Thailand, Taiwan, Malaysia, Indonesia,
Philippines and Hong Kong; Africa, including South Africa,
Mauritius, Kenya, Ghana, Ethiopia, Uganda and Nigeria; Central
Asia, including Azerbaijan; Middle East, including Kuwait and
Jordan; Pacific Island countries; Latin and Central American
countries; Europe, including Austria, Germany and Romania;
Australia and North America, including the USA and Canada.
This information is provided by RNS
The company news service from the London Stock Exchange
END
ACQEXLBBVZFEBBF
(END) Dow Jones Newswires
April 03, 2018 02:01 ET (06:01 GMT)
Beximco Pharma (LSE:BXP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Beximco Pharma (LSE:BXP)
Historical Stock Chart
From Apr 2023 to Apr 2024